Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.

Sonneveld MJ, Rijckborst V, Boucher CA, Zwang L, Beersma MF, Hansen BE, Janssen HL.

J Clin Virol. 2011 Jul;51(3):175-8. doi: 10.1016/j.jcv.2011.04.005. Epub 2011 May 17.

2.

Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.

Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, Cornberg M, Manns MP, Wedemeyer H.

J Clin Virol. 2011 Apr;50(4):292-6. doi: 10.1016/j.jcv.2010.12.008. Epub 2011 Jan 26.

PMID:
21273117
3.

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.

Hepatology. 2009 Apr;49(4):1141-50. doi: 10.1002/hep.22760.

PMID:
19338056
4.

Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.

Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.

Z Gastroenterol. 2011 Nov;49(11):1463-9. doi: 10.1055/s-0031-1281582. Epub 2011 Nov 8.

PMID:
22069045
6.

Serum HBsAg levels during peginterferon α-2a treatment with or without thymosin α-1 in HBeAg-positive chronic hepatitis B patients.

Song EY, Shin Y, Roh EY, Sue S, Park MH, Kim BH, Kim W, Yoon JH, Lee YJ, Park SJ, Jung EU, Lee JH, Myung SJ, Kim YJ, Lee HS.

J Med Virol. 2011 Jan;83(1):88-94. doi: 10.1002/jmv.21961.

PMID:
21108343
7.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
8.

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.

Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL.

Hepatology. 2010 Aug;52(2):454-61. doi: 10.1002/hep.23722.

PMID:
20683945
9.

Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.

Maylin S, Boyd A, Delaugerre C, Zoulim F, Lavocat F, Simon F, Girard PM, Lacombe K.

Clin Vaccine Immunol. 2012 Feb;19(2):242-8. doi: 10.1128/CVI.05454-11. Epub 2011 Dec 21.

10.

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.

Hepatology. 2010 Oct;52(4):1251-7. doi: 10.1002/hep.23844.

PMID:
20830787
11.

Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.

Zhou B, Liu M, Lv G, Zheng H, Wang Y, Sun J, Hou J.

J Viral Hepat. 2013 Jun;20(6):422-9. doi: 10.1111/jvh.12044. Epub 2013 Mar 25.

PMID:
23647959
12.

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.

Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW.

Antivir Ther. 2011;16(8):1249-57. doi: 10.3851/IMP1921.

PMID:
22155906
13.

Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.

Burdino E, Ruggiero T, Proietti A, Milia MG, Olivero A, Caviglia GP, Marietti M, Rizzetto M, Smedile A, Ghisetti V.

J Clin Virol. 2014 Aug;60(4):341-6. doi: 10.1016/j.jcv.2014.05.013. Epub 2014 Jun 2.

14.

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1462-8.

PMID:
18054753
15.

Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

Peng CY, Lai HC, Li YF, Su WP, Chuang PH, Kao JT.

Aliment Pharmacol Ther. 2012 Feb;35(4):458-68. doi: 10.1111/j.1365-2036.2011.04973.x. Epub 2012 Jan 8.

16.

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.

Hepatology. 2012 Jul;56(1):67-75. doi: 10.1002/hep.25636. Epub 2012 Apr 25.

PMID:
22307831
17.

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients.

Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, Gitto S, Galli C, Furlini G, Bernardi M, Andreone P.

J Viral Hepat. 2011 Oct;18(10):e468-74. doi: 10.1111/j.1365-2893.2011.01473.x. Epub 2011 Jun 1.

PMID:
21914065
18.

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL.

Hepatology. 2013 Sep;58(3):872-80. doi: 10.1002/hep.26436. Epub 2013 Jul 29.

PMID:
23553752
19.

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.

J Gastroenterol Hepatol. 2011 Oct;26(10):1527-35. doi: 10.1111/j.1440-1746.2011.06766.x.

PMID:
21557773
20.

Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.

Liao CC, Hsu CW, Gu PW, Yeh CT, Lin SM, Chiu CT.

Biomed J. 2015 May-Jun;38(3):250-6. doi: 10.4103/2319-4170.143485.

Supplemental Content

Support Center